[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343048-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343048-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","target-driven-tissue-agnostic-drug-approvalsa-new-path-of-drug-development","Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development","","Regulatory approvals for tumor-agnostic therapies have transformed drug development from histology-based models toward biomarker-driven strategies centered on shared genomic features across multiple cancers. Basket-like trials with multiple cohorts enable assessment of pan-cancer efficacy and toxicity while supporting eight FDA approvals. The review covers immune checkpoint inhibitors and targeted agents, detailing regulatory pathways and clinical performance, including biomarker-specific efficacy considerations and the evolving debate around biomarkers. It also emphasizes the biostatistical framework required to design these trials and interpret results for personalized oncology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/target-driven-tissue-agnostic-drug-approvalsa-new-path-of-drug-development/343048/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/target-driven-tissue-agnostic-drug-approvalsa-new-path-of-drug-development/343048.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does tumor-agnostic drug development focus on compared with traditional approaches?","Question",{"text":63,"@type":64},"It targets a common genomic biomarker across multiple cancers regardless of histology, instead of relying on histology-based models of drug development.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which types of tumor-agnostic therapies are reviewed in this article?",{"text":68,"@type":64},"The review focuses on immune checkpoint inhibitors and targeted therapy agents that have received FDA tumor-agnostic approvals.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are basket-like clinical trials important for tumor-agnostic approvals?",{"text":72,"@type":64},"They include multiple cohorts, allowing clinicians to evaluate pan-cancer efficacy and toxicity using the shared biomarker rationale.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343048,1791001491,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","cancers   \nReview  \nTarget-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development  \nKyaw Z. Thein 1,2,3, *, Yin M. Myat 4,5, Byung S. Park 6,7, Kalpana Panigrahi 5 and Shivaani Kummar 8  \nCitation: Thein, K.Z.; Myat, Y.M.; Park, B.S.; Panigrahi, K.; Kummar, S. Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development. Cancers 2024, 16, 2529 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16142529  \nAcademic Editors: Ellen Lori Weisberg and Konstantinos Dimas  \nReceived: 22 June 2024  \nAccepted: 6 July 2024  \nPublished: 13 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Hematology and Medical Oncology, Comprehensive Cancer Centers of Nevada—Central Valley, 3730 S Eastern Ave, Las Vegas, NV 89169, USA  \n2 Department of Medicine, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), 4505 S, Maryland Pkwy, Las Vegas, NV 89154, USA  \n3 College of Osteopathic Medicine, Touro University Nevada, Touro College and University System,  \n874 American Pacific Dr, Henderson, NV 89014, USA  \n4 Belfield Campus, University College Dublin (UCD) School of Medicine, D04 V1W8 Dublin, Ireland; [ym.myat8@gmail.com](ym.myat8@gmail.com)  \n5 Department of Internal Medicine, One Brooklyn Health—Interfaith Medical Center Campus, 1545, Atlantic Avenue, Brooklyn, NY 11213, USA; [kpanigrahi@interfaithmedical.org](kpanigrahi@interfaithmedical.org)  \n6 OHSU-PSU School of Public Health, Portland, OR 97201, USA; [parkb@ohsu.edu](parkb@ohsu.edu)  \n7 Biostatistics Shared Resource, OHSU Knight Cancer Institute, OHSU School of Medicine, Portland, OR 97239, USA  \n8 Division of Hematology & Medical Oncology, Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA; [kummar@ohsu.edu](kummar@ohsu.edu)  \n* Correspondence: [kyaw.thein@usoncology.com](kyaw.thein@usoncology.com); Tel.: +1-702-553-6547; Fax: +1-702-952-3381  \nSimple Summary: Precision oncology is at the forefront of personalized cancer care, utilizing tumoragnostic therapies that target specific biomarkers, such as tumor mutational burden, microsatellite instability, mutations, or fusions, regardless of cancer type. This review aims to provide a comprehensive summary of the immune checkpoint inhibitors and the targeted therapies approved by the US Food and Drug Administration (FDA) for tumor-agnostic use. We thoroughly reviewed pembrolizumab, dostarlimab, larotrectinib, entrectinib, selpercatinib, dabrafenib plus trametinib, and trastuzumab deruxtecan across eight indications, detailing their efficacy, toxicity, and regulatory history. Additionally, we highlight the critical role of biostatistics in designing the clinical trials necessary for evaluating these treatments. These insights advance our understanding of biomarkerdriven approaches, guide future research directions, and support the development of more effective, personalized cancer treatments across diverse histology.  \nAbstract: The regulatory approvals of tumor-agnostic therapies have led to the re-evaluation of the drug development process. The conventional models of drug development are histology-based. On the other hand, the tumor-agnostic drug development of a new drug (or combination) focuses on targeting a common genomic biomarker in multiple cancers, regardless of histology. The basket-like clinical trials with multiple cohorts allow clinicians to evaluate pan-cancer efficacy and toxicity. There are currently eight tumor agnostic approvals granted by the Food and Drug Administration (FDA) . This includes two immune checkp","cbCaileCfppzVbPh","https://ap.wps.com/l/cbCaileCfppzVbPh","pdf",2024501,24,"English","# Introduction\n## Regulatory approval shift to tumor-agnostic development\n## Biomarker-driven rationale and basket trials\n# Tumor-agnostic therapies and clinical evidence\n## Immune checkpoint inhibitors\n## Targeted therapies by biomarker\n# Clinical trial design and role of biostatistics\n## Trial evaluation and future research directions","[{\"question\":\"What does tumor-agnostic drug development focus on compared with traditional approaches?\",\"answer\":\"It targets a common genomic biomarker across multiple cancers regardless of histology, instead of relying on histology-based models of drug development.\"},{\"question\":\"Which types of tumor-agnostic therapies are reviewed in this article?\",\"answer\":\"The review focuses on immune checkpoint inhibitors and targeted therapy agents that have received FDA tumor-agnostic approvals.\"},{\"question\":\"Why are basket-like clinical trials important for tumor-agnostic approvals?\",\"answer\":\"They include multiple cohorts, allowing clinicians to evaluate pan-cancer efficacy and toxicity using the shared biomarker rationale.\"}]","Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development | PDF",1790049594,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ac5c8cc75d9c346bd003e3ff67a4d8a.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39039b600637b8c0042ad375755bdbcb.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7af34d7842d705c0ef03aecb315eac37.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60efae2b7181ec634be8e999ecc5d48d.webp",980,1385]